KURA ONCOLOGY INC. -

Kura Oncology to Report Third Quarter 2022 Financial Results  

27 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

26 Oct 2022 07:30:01 By Nasdaq GlobeNewswire

Kura Oncology to Participate in H.C. Wainwright Global Investment Conference

01 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Second Quarter 2022 Financial Results

03 Aug 2022 16:03:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

02 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Report Second Quarter 2022 Financial Results

27 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in Three Upcoming Investor Conferences

26 May 2022 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports First Quarter 2022 Financial Results

04 May 2022 16:05:01 By Nasdaq GlobeNewswire

Kura Oncology to Report First Quarter 2022 Financial Results

27 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

08 Apr 2022 13:00:00 By Nasdaq GlobeNewswire

Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting

08 Mar 2022 17:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in Two Upcoming Investor Conferences

28 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results

24 Feb 2022 16:03:00 By Nasdaq GlobeNewswire

Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results

17 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in SVB Leerink Global Healthcare Conference

10 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Expands Leadership Team with Key Promotions

01 Feb 2022 16:01:00 By Nasdaq GlobeNewswire

Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

20 Jan 2022 16:01:00 By Nasdaq GlobeNewswire

Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

16 Dec 2021 09:16:22 By Nasdaq GlobeNewswire

Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

13 Dec 2021 10:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax

13 Dec 2021 07:00:01 By Nasdaq GlobeNewswire